Eva-based transdermal matrix system for the administration of an estrogen and/or a progestogen
First Claim
1. A self-adhesive transdermal matrix system for the administration by percutaneous route of a hormone, said system, which comprises a support and self-adhesive matrix, having a matrix consisting essentially of:
- (a) 40 to 60 parts by weight of an ethylene/vinyl acetate copolymer,(b) 5 to 20 parts by weight of a cellulose compound,(c) 35 to 55 parts by weight of at least one compound selected from the group consisting of;
crotamiton,N-substituted 2-pyrrolidones of the formula I, ##STR3## in which the R group represents a (C1 -C15)-alkyl, cyclohexyl or 2 - hydroxyethyl group, and higher C12 -C20 aliphatic alcohols, and(d) 0.01 to 7 parts by weight of a hormone selected from the group consisting of estrogen compounds, progestogen compounds and mixtures thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to a new self-adhesive transdermal matrix system for the administration of a hormone by percutaneous route, said system which comprises a support and self-adhesive matrix, having a matrix comprising:
(a) 40 to 60 parts by weight of an ethylene/vinyl acetate copolymer,
(b) 5 to 20 parts by weight of a cellulosic material,
(c) 35 to 55 parts by weight of at least one compound selected from the group consisting of: crotamiton, N-substituted 2-pyrrolidones of the formula I, ##STR1## in which the R group represents a (C1 -C15)-alkyl, cyclohexyl or 2-hydroxyethyl group, and higher C12 -C20 aliphatic alcohols, and
(d) 0,01 to 7 parts by weight of a hormone selected from the group consisting of estrogen components, progestogen components and mixtures thereof.
It also relates to a method for preparing this transdermal matrix system.
-
Citations
29 Claims
-
1. A self-adhesive transdermal matrix system for the administration by percutaneous route of a hormone, said system, which comprises a support and self-adhesive matrix, having a matrix consisting essentially of:
-
(a) 40 to 60 parts by weight of an ethylene/vinyl acetate copolymer, (b) 5 to 20 parts by weight of a cellulose compound, (c) 35 to 55 parts by weight of at least one compound selected from the group consisting of; crotamiton, N-substituted 2-pyrrolidones of the formula I, ##STR3## in which the R group represents a (C1 -C15)-alkyl, cyclohexyl or 2 - hydroxyethyl group, and higher C12 -C20 aliphatic alcohols, and (d) 0.01 to 7 parts by weight of a hormone selected from the group consisting of estrogen compounds, progestogen compounds and mixtures thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
-
Specification